Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Breast Neoplasms

All Drugs and Chemicals

Antibodies

Immunoglobulins

YL202 is provided as the lyophilized powder, 200 mg/vial. Locally advanced or metastatic NSCLC patients will be given YL202 by intravenously once every 3 weeks (Q3W) as a cycle.

YL202 is provided as the lyophilized powder, 200 mg/vial. Locally advanced or metastatic BC patients will be given YL202 by intravenously once every 3 weeks (Q3W) as a cycle.

YL202 is provided as the lyophilized powder, 200 mg/vial. Locally advanced or metastatic HNSCC patients will be given YL202 by intravenously once every 3 weeks (Q3W) as a cycle.

YL202 is provided as the lyophilized powder, 200 mg/vial. Other locally advanced cancer patients will be given YL202 by intravenously once every 3 weeks (Q3W) as a cycle.

For each patient, YL202 should be intravenously infused over 60±10 min.

YL202 should be intravenously infused

Coordinator Clinical operation director

Coordinator

Dezhi Clinical Operation derictor

Coordinator Clincial operation director

Coordinator RA

Coordinator Clinial Operation director

This study is a multicenter, open-label, phase II study of YL202 in China to evaluate the efficacy, safety, and PK characteristics of YL202 in the following selected patients with advanced solid tumors.

This study is a multicenter, open-label, phase II study of YL202 in China to evaluate the efficacy, safety, and PK characteristics of YL202 in the advanced NSCLC/BC/HNSCC/colorectal cancer/HER2-positive gastric cancer/cervical cancer/ovarian cancer and etc.

A Study of YL202 in Selected Patients With Advanced Solid Tumors

A Multicenter, Open-Label, Phase II Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of YL202 in Selected Patients With Advanced Solid Tumors

ORR: defined as the proportion of patients who achieved a best overall response of complete response (CR) or partial response (PR).

MediLink Therapeutics (Suzhou) Co., Ltd.

Breast Diseases

Skin Diseases

YL202 is provided as the lyophilized powder, 200 mg/vial. Triple-negative breast cancer (TNBC) patients will be given YL202 by intravenously once every 3 weeks (Q3W) as a cycle.

YL202 is provided as the lyophilized powder, 200 mg/vial. HR-positive breast cancer with HER2-Zero-expression and HER2-Low-expression patients will be given YL202 by intravenously once every 3 weeks (Q3W) as a cycle.

YL202 is provided as the lyophilized powder, 200 mg/vial. Breast cancer patients who have previously failed treatments of HER2-ADC or TROP2-ADC (excluding HER2+ patients, ie, HER2 IHC 3+ or IHC 2+/ISH+ patients) will be given YL202 by intravenously once every 3 weeks (Q3W) as a cycle.

This study is a multicenter, open-label, phase 2 clinical study to evaluate the efficacy, safety and pharmacokinetics of YL202 in patients with locally advanced or metastatic breast cancer with TNBC, HR-positive, HER2-zero-expression or HER2-low-expression

A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC

A Multicenter, Open-Label, Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With Locally Advanced or Metastatic Breast Cancer With TNBC, HR-Positive, HER2-Zero-expression or HER2-Low-expression

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Study of YL202 in Selected Patients With Advanced Solid Tumors	NCT06107686	NSCLC Breast Cancer HNSCC Locally Advance...	YL202 should be...	18 Years - 75 Years	MediLink Therapeutics (Suzhou) Co., Ltd.
A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC	NCT06439771	Locally Advance...	YL202 should be...	18 Years - 75 Years	MediLink Therapeutics (Suzhou) Co., Ltd.
A Study of YL202 in Selected Patients With Advanced Solid Tumors	NCT06107686	NSCLC Breast Cancer HNSCC Locally Advance...	YL202 should be...	18 Years - 75 Years	MediLink Therapeutics (Suzhou) Co., Ltd.

Spots Global Cancer Trial Database for yl202 should be intravenously infused